These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 7470395)

  • 1. An evaluation of chromogenic substrates in the control of oral anticoagulant therapy.
    Latallo ZS; Thomson JM; Poller L
    Br J Haematol; 1981 Feb; 47(2):307-18. PubMed ID: 7470395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An assessment of an amidolytic assay for factor VII in the laboratory control of oral anticoagulants.
    Poller L; Thomson JM; Bodzenta A; Easton AC; Latallo ZS; Chmielewska J
    Br J Haematol; 1981 Sep; 49(1):69-75. PubMed ID: 7272230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of chromogenic peptide substrates in the determination of clotting factors II, VII, IX and X in normal plasma and in plasma of patients treated with oral anticoagulants.
    van Dieijen-Visser MP; van Wersch J; Brombacher PJ; Rosing J; Hemker HC; van Dieijen G
    Haemostasis; 1982; 12(3):241-55. PubMed ID: 7141303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between British Comparative Thromboplastin (BCT) and a factor II-VII-X determination method (simplastin A) based on fresh plasma samples from dicoumarol-treated patients.
    Korsan-Bengtsen K; Johsen M; Pehrsson NG
    Thromb Haemost; 1977 Feb; 37(1):98-103. PubMed ID: 65801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral anticoagulant control with a chromogenic substrate: calibration, precision and cost.
    Famodu AA; Ingram GI
    Clin Lab Haematol; 1982; 4(1):27-39. PubMed ID: 7067373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience with chromogenic substrates in studies of clotting and fibrinolytic systems.
    Chmielewska J; Latallo ZS
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):111-4. PubMed ID: 6177591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further evaluation of an automated amidolytic factor X assay in monitoring anti-vitamin K treatment.
    van Wijk EM; Kahlé LH; Jeletich A; ten Cate JW
    Scand J Haematol; 1982 Aug; 29(2):105-14. PubMed ID: 6813960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a new chromogenic assay for factor VII and its application in patients on oral anticoagulant treatment.
    Avvisati G; ten Cate JW; van Wijk EM; Kahlé LH; Mariani G
    Br J Haematol; 1980 Jun; 45(2):343-52. PubMed ID: 7437329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of coagulation factors (II-VII-X) and kaolin partial thromboplastin time by the LKB 8600 Reaction Rate Analyser.
    Hjorth B; Kjaersgaard E
    Scand J Clin Lab Invest; 1977 Feb; 37(1):15-20. PubMed ID: 616022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A clinical evaluation of automated chromogenic tests as substitutes for conventional prothrombin time and activated partial thromboplastin time tests.
    Duncan A; Bowie EJ; Owen CA; Fass DN
    Clin Chem; 1985 Jun; 31(6):853-5. PubMed ID: 3995763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance control of oral anticoagulant therapy by a chromogenic substrate assay for factor X.
    Erskine JG; Walker ID; Davidson JF
    J Clin Pathol; 1980 May; 33(5):445-8. PubMed ID: 7400342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to measure factor VII and factor VII activation.
    Osterud B
    Haemostasis; 1983; 13(3):161-8. PubMed ID: 6350121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Blood coagulation monitoring in oral anticoagulant therapy using chromogenic substances].
    Pindur G; Seifried E; Joos A; Rasche H
    Med Lab (Stuttg); 1981; 34(3):88-91. PubMed ID: 7231353
    [No Abstract]   [Full Text] [Related]  

  • 14. [Monitoring anticoagulant treatment with the KEM-O-MAT 2HP autoanalyzer].
    Laharrague P; Leleu T; Poignot JL; Cambus JP; Biermé R
    Nouv Rev Fr Hematol (1978); 1983; 25(2):107-12. PubMed ID: 6866753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical evaluation in liver diseases of a new blood coagulation test for the determination of factors II, VII and X].
    Pagliano FM; Cestari G; Slucca P
    Arch Sci Med (Torino); 1976; 133(4):315-20. PubMed ID: 1023839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance control of oral anticoagulant therapy by an automated chromogenic substrate assay of factor X.
    Erskine JG; Walker ID; Davidson JF
    Clin Lab Haematol; 1982; 4(2):179-86. PubMed ID: 7116798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Traces of factor VIIa modulate thromboplastin sensitivity to factors V, VII, X, and prothrombin.
    Smith SA; Comp PC; Morrissey JH
    J Thromb Haemost; 2006 Jul; 4(7):1553-8. PubMed ID: 16839353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a centrifugal analyzer in coagulation testing.
    Hills LP; Lorenzi-Anderson M; Huey EE; Tiffany TO
    Semin Thromb Hemost; 1983 Jul; 9(3):217-27. PubMed ID: 6612352
    [No Abstract]   [Full Text] [Related]  

  • 19. Chromogenic substrate (S-2222) factor X assays in the follow-up of coumarin treated patients. No advantage over prothrombin time and/or thrombotest.
    Girolami A; Saggin L; Gazzetta R; Saltarin P
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(4):610-6. PubMed ID: 6170557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A circulating anticoagulant specific for factor V.
    Handley DA; Duncan BM
    Pathology; 1969 Oct; 1(4):265-72. PubMed ID: 5406477
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.